Details checkedClinical trial listing onlyCheckedregistry

Kartal Oral Methylprednisolone versus Intratympanic Dexamethasone SSNHL Study

Also known as: Methylprednisolone (drug), oral methylprednisolone treatment, intratympanic dexamethasone treatment, NCT06968507

Government-led study

Primary source

Sponsor / Institution

Government-led study

Program Type

Therapeutic

Modality

Steroid/Anti-inflammatory

Stage

Phase 4

Status

Active

Target Gene

—

Route / Mode

Oral methylprednisolone versus intratympanic dexamethasone

Confidence

84%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-10

Geography

Turkey

Population

adult, sudden, sensorineural

Trial IDs

Mechanism

Recruiting Phase 4 government-led comparison of oral methylprednisolone treatment versus intratympanic dexamethasone treatment in sudden sensorineural hearing loss.

Indications

Hearing Loss Sensorineural Hearing Loss Sudden Sensorineural Hearing Loss

Notes

Verified as a focused corticosteroid-comparison study now split out from the broad dexamethasone cluster. It should be shown as a government-led study-level comparison rather than a standalone methylprednisolone product program.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, mechanism...

IDs: NCT06968507

Open

Key Events

2025-05-20

Registry lists estimated start for oral methylprednisolone versus intratympanic dexamethasone SSNHL study

Clinical Trials (1)

NCT06968507

Data Checks